CDK9-IN-27
CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC50s: 0.424 μM) . CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC50s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research[1].
Product Specifications
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk9-in-27.html
Solubility
10 mM in DMSO
Smiles
ClC(C=C1)=CC=C1C(C(C(OCC)=O)=C(N)N2CC3=NC4=CC=CC=C4N3)=C(C#N)C2=O
Molecular Formula
C23H18ClN5O3
Molecular Weight
447.87
References & Citations
[1]Husseiny EM, et al. Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors. Future Med Chem. 2023 Aug 16.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb1597754 100 µL
Myocardin Rabbit Polyclonal Antibody (PerCP-Cy5.5)
Sign In for Pricing
View Details 